PF-04523655 (REDD14NP)

PF-04523655 · Quark Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PF-04523655 (REDD14NP), covering 2012-10-10 to 2012-10-10. Get the full timeline:

Most recent: Clinical Trial Update: Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD) [Phase 1]

See pricing